Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$143.82
-2.7%
$210.88
$143.40
▼
$479.79
$19.26B0.421.62 million shs2.32 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$50.52
-1.6%
$42.62
$23.62
▼
$59.97
$31.53B0.732.59 million shs2.79 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.60
-0.9%
$37.22
$19.96
▼
$42.50
$27.97B1.236.57 million shs3.97 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$63.34
-2.4%
$57.39
$26.76
▼
$68.03
$9.57B1.892.12 million shs2.09 million shs
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-1.06%-5.64%-35.93%-37.42%-67.92%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+0.75%-0.75%+31.43%+53.51%+67.98%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.59%-2.58%+11.57%+7.33%+91.54%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
-1.88%+0.50%+18.98%+19.55%+113.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$143.82
-2.7%
$210.88
$143.40
▼
$479.79
$19.26B0.421.62 million shs2.32 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$50.52
-1.6%
$42.62
$23.62
▼
$59.97
$31.53B0.732.59 million shs2.79 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.60
-0.9%
$37.22
$19.96
▼
$42.50
$27.97B1.236.57 million shs3.97 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$63.34
-2.4%
$57.39
$26.76
▼
$68.03
$9.57B1.892.12 million shs2.09 million shs
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-1.06%-5.64%-35.93%-37.42%-67.92%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+0.75%-0.75%+31.43%+53.51%+67.98%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.59%-2.58%+11.57%+7.33%+91.54%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
-1.88%+0.50%+18.98%+19.55%+113.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.63
Moderate Buy$287.7095.15% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3.00
Buy$53.505.56% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.79
Moderate Buy$46.8220.07% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.78
Moderate Buy$63.00-2.26% Downside

Current Analyst Ratings Breakdown

Latest TGTX, ALNY, GMAB, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Boost Price TargetOutperform$292.00 ➝ $293.00
11/18/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
DowngradeBuy (B) ➝ Buy (B-)
11/18/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
DowngradeNeutral
11/18/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Set Price Target$254.00
11/17/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Reiterated RatingSell (D-)
11/17/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Lower Price TargetNeutral$290.00 ➝ $205.00
11/17/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Lower Price TargetBuy$455.00 ➝ $250.00
11/16/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$46.00 ➝ $48.00
11/13/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Lower Price TargetEqual Weight$57.00 ➝ $56.00
11/10/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$47.00 ➝ $48.00
11/9/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
UpgradeHold (C+) ➝ Buy (B-)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B5.32$2.76 per share53.43$26.91 per share5.48
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B8.50$1.60 per share31.67$10.15 per share4.99
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,420.43N/AN/A$6.34 per share6.15
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$616.29M15.81$2.73 per share23.60$3.79 per share17.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$19.267.6618.11N/A52.85%155.33%44.81%N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.1743.3531.882.0516.97%13.67%6.42%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.63N/AN/AN/A-838.21%-22.03%-20.55%2/5/2027 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$447.18M$0.6697.7122.545.2111.81%18.82%7.78%N/A

Latest TGTX, ALNY, GMAB, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.3593$0.35-$0.0093$0.35$245.47 million$259.94 million
11/5/2026Q3 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.36$0.56+$0.20$0.5510$1.20 billion$1.19 billion
10/29/2026Q3 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.66$16.26+$14.60$15.72$1.43 billion$1.46 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.18
2.48
2.43
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.74
2.45
2.43
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
15.56
15.56
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.30
4.50
3.75

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
8.80%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
8.87%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.94 million132.79 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029624.06 million614.45 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
721724.56 million660.80 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
399151.15 million137.74 millionOptionable

Recent News About These Companies

TG Therapeutics (NASDAQ:TGTX) Shares Down 4.8% After Earnings Miss

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$143.82 -4.00 (-2.71%)
Closing price 04:00 PM Eastern
Extended Trading
$144.56 +0.74 (+0.51%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$50.52 -0.83 (-1.61%)
Closing price 03:58 PM Eastern
Extended Trading
$50.50 -0.02 (-0.04%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$38.60 -0.36 (-0.93%)
Closing price 03:58 PM Eastern
Extended Trading
$38.65 +0.05 (+0.14%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$63.34 -1.54 (-2.37%)
Closing price 04:00 PM Eastern
Extended Trading
$63.72 +0.38 (+0.61%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.